Evidence map›Paper›PMID 28605172›Full record

ArticleJournal of the International AIDS Society2017

Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil.

David Martin, Paula M Luz, Jordan E Lake, Jesse L Clark, Dayse P Campos, Valdilea G Veloso, Ronaldo I Moreira, Sandra W Cardoso, Jeffrey D Klausner, Beatriz Grinsztejn

Abstract readValidation Study
In one paragraph

Article in Journal of the International AIDS Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Factors associated with adherence to antiretroviral therapy in HIV-infected subjects and the use of indicators to characterize the treatment adhesion profile.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

David MartinDepartment of Emergency Medicine, Highland Hospital, Oakland, CA, USA.
Paula M LuzInstituto Nacional de Infectologia (INI), Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
Jordan E LakeDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Jesse L ClarkDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Dayse P CamposInstituto Nacional de Infectologia (INI), Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
Valdilea G VelosoInstituto Nacional de Infectologia (INI), Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
Ronaldo I MoreiraInstituto Nacional de Infectologia (INI), Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
Sandra W CardosoInstituto Nacional de Infectologia (INI), Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.
Jeffrey D KlausnerDepartment of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Beatriz GrinsztejnInstituto Nacional de Infectologia (INI), Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil.

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Nina Thawata Harawa · 1997 to 2026
$53.5M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
South American Program in HIV Prevention Research (SAPHIR)R25MH087222 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JESSE LAWTON CLARK, Karin Nielsen · 2011 to 2026
$3.9M
Inflammation, Fibrosis and End-Organ Disease in HIV-Infected AdultsK23AI110532 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LAKE, JORDAN E · 2014 to 2018
$937k
NIAID NIH HHS K23 AI110532NIAID NIH HHS UM1 AI069476NIMH NIH HHS P30 MH058107NIMH NIH HHS R25 MH087222
6 · The paper itself

Abstract

introductionPharmacy adherence measures such as pharmacy dispensing ratios (PDRs) have previously been shown to be predictive of virologic outcomes. We aimed to determine the optimal interval of PDR assessment for predicting virologic failure for HIV-infected patients on antiretroviral therapy (ART).

methodsUsing national Brazilian ART pharmacy refill data, we examined PDRs for patients ≥18 years of age with at least one HIV RNA level ≥180 days after ART initiation on or after 1 January 2011. Patients with a documented ART change ≤270 days prior to viral load test date were excluded. Logistic regression models were used to describe associations between virologic failure, defined as an HIV RNA level ≥400 copies/mL and PDRs, defined as the number of days index drug dispensed (non-nucleoside reverse-transcriptase inhibitor or protease inhibitor) per 180- and 90-day, interval preceding viral load testing, adjusting for sex, age, race, time since ART initiation and index drug. Backward elimination of insignificant variables was performed after adjusting for PDR. A predictive probability of virologic failure was calculated using the corresponding odds ratios for the PDR and any other significant variables. The diagnostic performance of the PDR interval was assessed by calculating the area under the receiver operating characteristic curve (AUROC) for the predictive probability with respect to virologic failure.

conclusionsThe validation and use of the pharmacy dispensing ratio using public pharmacy refill data could aid in early identification of patients with poor adherence and prevent development of treatment failure and drug resistance in Brazil.

Indexed as

PrescriptionsTreatment FailureAdultAnti-HIV AgentsBrazilFemaleHIV InfectionsHumansMaleMiddle AgedROC CurveViral LoadAnti-HIV Agentsadherenceantiretroviral therapyBrazilcohort studiespharmacy refillviral load

Identifiers

PMID28605172
PMCPMC5515012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.